<DOC>
	<DOCNO>NCT02357290</DOCNO>
	<brief_summary>Children age 5-17 year old display symptoms emotional dysregulation ( explosiveness , mood swing , irritability , and/or violent behavior ) invite participate 12-week research study determine effectiveness safety natural treatment N-acetylcysteine ( NAC ) child emotional behavioral problem . After undergo comprehensive evaluation medical doctor specialty area , child find eligible participate research study treat NAC . Following evaluation period , research study require 12 weekly visit , either office phone , effort closely monitor child 's response medication . Eligible participant receive study-related evaluation weekly study visit study doctor cost .</brief_summary>
	<brief_title>Open-Label Study N-Acetylcysteine Children Adolescents 5-17 With Bipolar Spectrum Disorders</brief_title>
	<detailed_description>This 12-week , open-label study NAC treatment bipolar disorder child adolescent . Subjects include youth age 5-17 year bipolar spectrum disorder ( type I , II , NOS ) , mixed , manic , hypomanic state , accord Diagnostic Statistical Manual Mental Disorders , Fifth Edition DSM-5 ( American Psychiatric Association , 2013 ) . The primary outcome measure improvement manic symptom measure Young Mania Rating Scale ( YMRS ) improvement depressive symptom measure Child Depression Rating Scale ( CDRS ) . Bipolar diagnosis make accord DSM-5 clinical evaluation Child Psychiatrist confirm use Schedule Affective Disorders Schizophrenia School-Age Children - Epidemiological Version ( K-SADS-E ) ( Orvaschel , 1994 ) . All subject must YMRS score least 20 . Only patient respond current treatment regimen taper medication ; youth concomitant psychiatric medication permit continue medication list concomitant medication section .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Male female subject , 517 year age Subjects must DSMIV diagnosis bipolar spectrum disorder ( type I , II , Not Otherwise Specified ) currently display mixed , manic , hypomanic symptom ( without psychotic feature ) accord clinical assessment base DSMIV confirm structure diagnostic interview Subjects legal representative must level understanding sufficient communicate intelligently investigator study coordinator cooperate test examination require protocol Subjects legal representative must consider reliable . Each subject his/her authorized legal representative must understand nature study . The subject 's authorized legal representative must provide write consent subject must provide write assent . Subjects must initial score YMRS least 20 . Investigator his/her immediate family ( defined investigator 's spouse , parent , child , grandparent , grandchild ) Serious unstable illness include hepatic , rental , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease Uncorrected hypothyroidism hyperthyroidism History sensitivity Nacetylcysteine , history intolerance Nacetylcysteine , nonresponder 2 month treatment adequate dos determine clinician Severe allergy multiple adverse drug reaction Current past history seizure Current DSMIV substance use , abuse , dependence Judged clinically serious suicidal risk Current diagnosis schizophrenia Pregnancy CSSRS score â‰¥ 4 IQ &lt; 70</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>mania</keyword>
	<keyword>temper tantrum</keyword>
	<keyword>irritability</keyword>
	<keyword>mood</keyword>
	<keyword>bipolar</keyword>
</DOC>